U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809919) titled 'A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects' on Aug. 26.
Brief Summary: The purpose of this first-in-human study is to generate the necessary safety, tolerability, and pharmacokinetics (PK) information that will support further clinical development of LXE408 for the treatment of patients with visceral leishmaniasis and potentially Chagas disease.
Study Start Date: Dec. 21, 2018
Study Type: INTERVENTIONAL
Condition:
Visceral Leishmaniasis
Chagas Disease
Intervention:
DRUG: LXE408
LXE408 comes in film coated tablets and is taken orally.
DRUG: Placebo
LXE408 matching placeb...